Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $951K, compared with -$850K a year earlier. Trailing-twelve-month other income / expenses was -$13.7M.

Context

  • Other income / expenses amounted to 39.2% of revenue in FY2025, up 29.0 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $951K or moves back toward the trailing-twelve-month quarterly average of -$3.42M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$951K+107.3% QoQ
Last fiscal yearDec 2025
-$15.5M-364.4% YoY
LTMMar 2026
-$13.7M-653.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+211.9%——
1 year-364.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(15.5M) USD
Year-over-year change
-364.4%

Other Income / Expenses vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -653.1% is the 8th highest of 11, against a peer median of -20.3%.
  • Other income / expenses amounts to 39.6% of revenue for SGMO, versus a peer median of 50.2%.
SGMO Competitors
Other Income / Expenses for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$10.16M USD-24.2%—29.2%
OABIOmniAb, Inc.LTM Mar 2026$4.56M USD+71.8%+107.2%15.8%
IPHAInnate Pharma S.A.FY2025€4.25M EUR+101.9%—152.4%
IVVDInvivyd, Inc.LTM Mar 2026$4.17M USD-16.4%-23.0%7.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$1.59M USD+51.0%—50.2%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$3.08M USD-1482.5%—172.8%
CDXSCodexis, Inc.LTM Mar 2026-$6.03M USD+17.5%—7.7%
MOLNMolecular Partners AGLTM Mar 2026-CHF 6.37M CHF-427.8%——
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-$6.67M USD-1912.5%—342.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$13.7M USD-653.1%—39.6%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-$245.39M USD-713.9%—8295.7%
Peer median (excluding SGMO) —-20.3%+42.1%50.2%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.